Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

NCT03216343 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Chiauranib

Sponsor

Chipscreen Biosciences, Ltd.